<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24448861</identifier>
<setSpec>0717-6163</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Gutiérrez, Miguel A</dc:author>
<dc:author>Iruretagoyena, Mirentxu</dc:author>
<dc:author>Ibáñez, Sebastián</dc:author>
<dc:description xml:lang="en">For years the mainstay of antiphospholipid syndrome treatment has been anticoagulation and antiplatelet therapy, but the autoimmune nature of the disease, and complications of these therapies, created the need to develop new therapeutic strategies. New therapeutic alternatives inhibit at different levels, the cascade of events leading to the pro-thrombotic state characteristic of the antiphospholipid syndrome. We conducted a literature review of these new treatments, focusing on the pathophysiological bases that support them and their possible clinical applications.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Aug </dc:date>
<dc:title xml:lang="es">Nuevas estrategias en el tratamiento del síndrome antifosfolípido.</dc:title>
<dc:title xml:lang="en">[New alternatives for the treatment of antiphospholipid syndrome. A literature review].</dc:title>
<dc:publisher>Revista medica de Chile</dc:publisher>
</metadata>
</record>
</pubmed-document>
